Recent news on Gemcitabine

AUA 2007 - Plenary Session: State-of-the-Art "Novel Treatment ...  -  25 May 2007
UroToday,Gemcitabine has a favorable toxicity and a different mechanism of action. However, the only study that looked at it in the salvage setting showed only a 7%

AUA 2007 Plenary Session: SIU Lecture “What is New in the ...  -  25 May 2007
UroToday,Gemcitabine with cisplatin is less toxic with a similar response rate to MVAC. Paclitaxel with carboplatin for regionally advanced disease showed 5 year

Making Science Personal: Lilly  -  May 22, 2007
Ad-Hoc-News (Pressemitteilung),The company will present important data on GEMZAR(R) (gemcitabine HCl for injection), ALIMTA(R) (pemetrexed for injection), and enzastaurin,

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  Apr 27, 2007
CNW Telbec (Communiqués de presse),A higher percentage of patients were alive at 12 months in the group treated with Tarceva plus gemcitabine, compared to those treated with chemotherapy

SciClone Acquires Clinical-Stage Pancreatic Cancer Compound  -  Apr 26, 2007
PipelineReview.com (press release),Patients with advanced stages of pancreatic cancer are typically treated with chemotherapeutic agents such as gemcitabine, alone or in combination with

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  Apr 25, 2007
Earthtimes.orgNew results published by the Journal of Clinical Oncology show thatadding Tarceva (erlotinib) to gemcitabine chemotherapy significantlyimproves survival by

Oncolytics Biotech Inc. Announces 2007 First Quarter Results  -  Apr 27, 2007
CNW Telbec (Communiqués de presse),First Quarter Highlights << - Received approval for two UK clinical trials; one investigating REOLYSIN(R) in combination with gemcitabine and the other

Addition of Tarceva® to Gemzar® Improves Survival in Pancreatic Cancer  -  May 9, 2007
Cancer Consultants (press release),An international randomized trial has demonstrated that the addition of Tarceva® (erlotinib) to Gemzar® (gemcitabine) improves survival in patients with

OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study ...  -  Apr 25, 2007
PharmaLive.com (press release),In November 2005, the US Food and Drug Administration (FDA) approved the use of Tarceva (100 mg) in combination with gemcitabine for the first-line

Pharmexa starts pivotal phase III trial in the United States  -  May 4, 2007
PipelineReview.com (press release),Brief description of the trial In the PrimoVax trial, GV1001 will be tested side by side with the current standard treatment gemcitabine (Gemzar(R)),

Pharmexa starts pivotal phase III  -  May 3, 2007
Ad-Hoc-News (Pressemitteilung),Brief description of the trialIn the PrimoVax trial, GV1001 will be tested side by side with thecurrent standard treatment gemcitabine (Gemzar®),

MediGene Completes Patient Recruitment for Clinical Phase II Trial ...  -  Apr 25, 2007
PipelineReview.com (press release),The ongoing phase II trial is also designed to make the tumor more accessible for the gemcitabine which is administered simultaneously.

Teva wins FDA approval for generic Gemzar  -  May 8, 2007
Globes,...application (ANDA) to market its generic version of Eli Lilly and Co's (NYSE:LLY) cancer treatment Gemzar (Gemcitabine) for injection, 200 mg base/vial.

Teva Pharmaceutical (TEVA) Receives Tentative FDA Approval for ...  -  May 8, 2007
StreetInsider.com (subscription),...(ANDA) to market its generic version of Eli Lilly and Co's (NYSE: LLY) cancer treatment Gemzar (Gemcitabine) for injection, 200 mg base/vial.

Talabostat Clinical Program Put on Clinical Hold by FDA  -  May 22, 2007
PipelineReview.com (press release),...in combination with rituximab in advanced chronic lymphocytic leukemia and in combination with gemcitabine in Stage IV pancreatic cancer.

Cyclacel Pharmaceuticals Begins Phase II Study of Oral ...  -  Apr 30, 2007
PharmaLive.com (press release),..."Nucleoside analogs, such as gemcitabine, have significant activity in CTCL" said Dr. Duvic. "We are interested in evaluating sapacitabine because of its

Point Therapeutics Announces Interim Analysis to be Performed on ...  -  May 15, 2007
PharmaLive.com (press release),Point is also currently studying talabostat in a Phase 2 trial in combination with gemcitabine in Stage IV pancreatic cancer. In addition, Point has studied

Teva Announces Tentative Approval of Generic Gemzar for Injection  -  May 14, 2007
SpiritIndia,New Drug Application (ANDA) to market its generic version of Eli Lilly and Co's cancer treatment Gemzar® (Gemcitabine) for injection, 200 mg base/vial.

More hopes for pancreatic cancer patients treated with combination ...  -  May 4, 2007
TopCancerNews.com,An early online publication of the Journal of Clinical Oncology states that the addition to the targeted agent Tarceva (erlotinib) to Gemzar (gemcitabine)

Coley Pharmaceutical Group Reports First Quarter Financial Results  -  May 3, 2007
PR Newswire (press release),...safety and efficacy of PF-3512676 administered in combination with standard-of-care chemotherapy, gemcitabine/cisplatin, compared to chemotherapy alone,

Tarceva extends life of patients with pancreatic cancer  -  26 Apr 2007
Antara (press release),Basel (ANTARA News/PRNewswire-AsiaNet) - New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine

Market Report -- In Play (SCLN)  -  26 Apr 2007
MSN MoneyIn a previous phase 1 clinical trial evaluating RP101 in combination with gemcitabine, the current standard of care, to treat late-stage pancreatic cancer

Avantogen Oncology, Inc. Completes Major Transaction With SciClone ...  -  26 Apr 2007
Genetic Engineering News (press release),SciClone will develop and commercialize RP101, initially in combination with gemcitabine, for the treatment of pancreatic cancer in the US and Canada.

Oncolytics Biotech researchers demonstrate reovirus/gemcitabine  -  Apr 19, 2007
News-Medical.net,The researchers found that treatment of human colon cancer cell lines with the combination of REOLYSIN(R) and gemcitabine resulted in both in vitro and in

Oncolytics Biotech Inc., research collaborators demonstrate ...  -  Apr 18, 2007
SpiritIndia,Researchers concluded that the synergistic combination of Reolysin and gemcitabine is a promising therapeutic regimen for study in clinical trials.

Reovirus/Gemcitabine Combination Has Synergistic Effect Against ...  -  Apr 17, 2007
eMaxHealth.com,Oncolytics Biotech Inc. announces that a poster by Dr. Maureen E. Lane entitled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated

Curcumin, Also Known As Curry Powder, Has Anticancer Effects  -  Apr 22, 2007
Medical News Today (press release),Compared to the control, in all study groups curcumin was found to inhibit the growth of tumors in mice and to enhance the effects of both gemcitabine

Clinical Trials Update: April 19, 2007  -  Apr 19, 2007
Atlanta Journal Constitution (subscription),The purpose of this study is to test an investigational drug, vinflunine, in combination with gemcitabine in patients with transitional cell carcinoma who

Market Report -- In Play (ONCY)  -  Apr 17, 2007
MSN MoneyOncolytics Biotech Research collaborators demonstrate Reovirus/Gemcitabine combination has synergistic effect against human colon cancer cell lines Co

ERBITUX® Fails to Meet Primary Endpoint in Advanced Pancreatic ...  -  Apr 12, 2007
EndoNurse,NEW YORK -- ImClone Systems Incorporated and Bristol-Myers Squibb Company announced that a Phase III study of ERBITUX® (cetuximab) plus gemcitabine (a

Data Available from ERBITUX(R) Phase III Study in First-Line ...  -  Apr 12, 2007
Cancer Focus,ERBITUXterm(R) (Cetuximabterm) plus gemcitabine (a chemotherapyterm) in patients with locally advanced unresectable or metastaticterm pancreatic cancer

Erbitux Misses In Pancreatic Cancer, Dropping ImClone  -  Apr 11, 2007
BioWorld Online,The open-label, randomized trial, conducted by the Southwest Oncology Group, compared Erbitux and the chemotherapy gemcitabine (Gemzar, Eli Lilly & Co.

ImClone shares suffer as Erbitux pancreatic cancer trial fails  -  Apr 11, 2007
Pharma Times (subscription),The trial, which was conducted by the Southwest Oncology Group, compared Erbitux plus gemcitabine to gemcitabine alone in more than 700 patients with

Erbitux fails in pancreatic cancer study  -  Apr 10, 2007
United Press InternationalThe companies were testing the drug in a phase 3 trial, administering it in combination with the chemotherapy drug gemcitabine to patients with locally

Imclone And Bristol-Myers, Erbitux Phase III Study Did Not Meet ...  -  Apr 10, 2007
Trading Markets,Southwest Oncology Group, a cancer center network sponsored by the National Cancer Institute conducted the study, which compared Erbitux plus gemcitabine to

ImClone Systems, Bristol-Myers Say ERBITUX Phase III Study Fails ...  -  Apr 10, 2007
Trading Markets,...(BMY | charts | news | PowerRating), on Tuesday said that the Phase III study of ERBITUX or Cetuximab plus gemcitabine in patients with locally advanced

Scientists explain curcumin's anti-cancer mechanism  -  Apr 16, 2007
FoodNavigator-USA,One group continued to receive only curcumin supplements, while the others received curcumin in conjunction with the chemotherapy agent gemcitabine or

No Survival Benefit with Erbitux in Pancreatic Cancer  -  Apr 11, 2007
Cancerpage.com,The 700-patient trial compared Erbitux in combination with gemcitabine to gemcitabine alone in patients with pancreatic cancer that could not be surgically

ImClone's Erbitux flunks new cancer trial  -  Apr 10, 2007
CNNMoney.com...s chemotherapy Gemzar, or gemcitabine, with gemcitabine alone in patients whose cancer could not be surgically treated or had spread to other parts of the

ImClone's Erbitux Fails Pancreatic Cancer Trial  -  Apr 10, 2007
Reuters.uk,N: Quote, Profile , Research) chemotherapy Gemzar, or gemcitabine, with gemcitabine alone in patients whose cancer could not be surgically treated or had

Study Setback Rocks ImClone  -  Apr 10, 2007
TheStreet.comThe companies had hoped the Phase III trial would show Erbitux, when combined with gemcitabine chemotherapy, improved overall survival, but the primary

Erbitux fails pancreatic cancer trial  -  Apr 10, 2007
WIS,N) chemotherapy Gemzar, or gemcitabine, with gemcitabine alone in patients whose cancer could not be surgically treated or had spread to other parts of the

Breakthrough in cancer treatment could provide less traumatic ...  -  Apr 13, 2007
Daily Mail,Six genes showing the most dramatic effect were re-tested using the drugs vinorelbine and gemcitabine, with weaker results.

NutraCea Announces Appointment of Leo G. Gingras as Its New Chief ...  -  Apr 12, 2007
Financial News USA (press release),The study, conducted by the Southwest Oncology Group, compared Erbitux plus the chemotherapy gemcitabine with gemcitabine alone in more than 700 patients

Study results push ImClone shares down  -  Apr 10, 2007
International Herald Tribune,The study, conducted by the Southwest Oncology Group, compared Erbitux plus the chemotherapy agent gemcitabine with gemcitabine alone in more than 700

ImClone: Erbitux Falls Short on Pancreas  -  Apr 10, 2007
Forbes,Gemcitabine is the generic name for Eli Lilly & Co.'s Gemzar chemo drug. Pancreatic cancer is the most aggressive and difficult to treat of all cancers.

ImClone stock drops on Erbitux-chemo results  -  Apr 10, 2007
Crain's New York Business,Gemcitabine is the generic name for Eli Lilly & Co.'s Gemzar chemo drug. Erbitux is currently approved to treat colorectal cancer as well as head and neck

Market Report -- In Play (IMCL)  -  Apr 10, 2007
MSN MoneyIMCL and BMY announced that a Phase III study of Erbitux plus gemcitabine in patients with locally advanced unresectable or metastatic pancreatic cancer

UPDATE: ImClone (IMCL) ERBITUX Misses Survival Endpoint in ...  -  Apr 10, 2007
StreetInsider.com (subscription),ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced that a Phase III study of ERBITUX plus gemcitabine (a

Data Available From Erbitux® Phase III Study In First-Line ...  -  Apr 16, 2007
Medical News Today (press release),Phase III study of ERBITUX® (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer

Cancer Genes Linked to Chemotherapy Sensitivity  -  Apr 12, 2007
Genetic Engineering News (press release),...and tried the same test using chemotherapy drugs Vinorelbine and Gemcitabine, but the results were not as dramatic as those seen for Paclitaxel.

Eli Lilly sues Sun Pharma over patent for cancer drug  -  Apr 2, 2007
domain-B,While Eli Lilly's basic patent on the active pharmaceutical ingredient Gemcitabine hydrochloride will expire on November 15, 2010, another patent on the

Source: IRIS NEWS DIGEST (02 April 2007)  -  Apr 1, 2007
Myiris.com,Eli Lilly’s basic patent on the active pharmaceutical ingredient Gemcitabine hydrochloride will expire on November 15, 2010, another patent on the method to

Genes could ease pain of cancer treatment  -  Apr 11, 2007
The Herald,Less dramatic effects were seen with the chemotherapy drugs Vonorelbine and Gemcitabine. The results raise the possibility of lowering chemotherapy doses

Data Available from ERBITUX(R) Phase III Study in First-Line ...  -  Apr 10, 2007
PipelineReview.com (press release),...study compared ERBITUX plus gemcitabine to gemcitabine alone in more than 700 patients with pancreatic cancer in the first-line treatment setting.

Early stage pancreatic cancer expresses antigen targeted by ...  -  Apr 18, 2007
News-Medical.net,Although the radiolabeled PAM4 antibody was superior to gemcitabine alone, the combination of radiolabeled PAM4 antibody and gemcitabine was more active in

Sequential Chemotherapy Helpful in Advanced Lung Cancer  -  Mar 29, 2007
Cancerpage.com,In this context, she added, "the sequential regimen evaluated in our paper, with cisplatin and gemcitabine followed by weekly docetaxel as first-line

ImClone Systems Pulled Back On Study Results  -  Apr 10, 2007
Trading Markets,...midday Tuesday that a Phase III study of ERBITUX plus gemcitabine, in patients with locally advanced unresectable or metastatic pancreatic cancer,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional